Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma (Business Wire)
Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF. T3 Pharma has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer cells and tumor micro-environments. Despite the significant transformation of the cancer treatment landscape by immunotherapies, long-term remissions only occur in 15-20% of cancer patients. Boehringer Ingelheim aims to considerably increase this rate by utilizing complementary immuno-oncology platforms such as T-Cell Engagers (TcEs), oncolytic viruses, and cancer vaccines, which have the potential to turn cold tumors into hot ones, extending the benefits of immunotherapy to more patients in need.
Merck Expands Newest Biologics Testing Center in Shanghai (Company website)
FDA’s drug delivery device recall spree continues with Class I tag for B. Braun infusion pump (Fierce Pharma)
For the fourth time already this month, the FDA has issued a notice formally bestowing a Class I label—denoting a heightened risk of serious injury or death—upon a recall of yet another drug delivery device. This time around, the recall was initiated by B. Braun Medical, and it concerned the German devicemaker’s Infusomat Space volumetric infusion pump system.
Hermes Pharma, a German CDMO, plans to spend EUR 25 million euros to enhance its production capabilities for oral medicines. The funds will be used to buy new equipment, boost efficiency, increase production capacity and add storage space, the company said. The investment is expected to drive future growth for Hermes, which manufactures easy-to-swallow oral dosage forms such as orally disintegrating granules and chewable tablets.